

Please try another search
Investing.com - Fulgent Genetics (NASDAQ: FLGT) reported first quarter EPS of $-0.22, $0.30 better than the analyst estimate of $-0.52. Revenue for the quarter came in at $66.2M versus the consensus...
Investing.com - Fulgent Genetics (NASDAQ: FLGT) reported fourth quarter EPS of $-0.48, $0.08 better than the analyst estimate of $-0.56. Revenue for the quarter came in at $67.7M versus the consensus...
Fulgent Genetics, Inc. (NASDAQ:FLGT) reported Q4 EPS of ($0.48), $0.08 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $67.7 million versus the consensus estimate of...
Fulgent Genetics, Inc. (NASDAQ:FLGT) today announced the immediate availability of their new Beacon787 expanded carrier screening panel. Beacon787 will include a total of 787 genes associated with...
Fulgent Genetics, Inc. (FLGT) reported Q3 EPS of $0.06, $0.11 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $105.66 million versus the consensus estimate of $103.7...
Investing.com - Fulgent Genetics (NASDAQ:FLGT) reported on Monday third quarter earnings that missed analysts' forecasts and revenue that topped expectations. Fulgent Genetics announced earnings per...
Fulgent Genetics, Inc. (NASDAQ:FLGT) reported Q2 EPS of $0.78, $0.05 better than the analyst estimate of $0.73. Revenue for the quarter came in at $125.3 million versus the consensus estimate of...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review